Table 3.
Results of the meta-analysis from different genetic models
| No. of cases/controls | A vs G | AA vs GG | AA+GA vs GG | AA vs.GA+GG | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P | I2 | P (Q-test) | OR (95% CI) | P | I2 | P (Q-test) | OR (95% CI) | P | I2 | P (Q-test) | OR (95% CI) | P | I2 | P (Q-test) | ||
| Total | 11,276/14,523 | 1.10(0.1.00–1.21) | 0.051 | 79.1% | <0.001 | 1.22(1.01–1.48) | 0.042 | 74.9% | <0.001 | 1.16(1.02–1.33) | 0.026 | 68.3% | <0.001 | 1.12(1.00–1.26) | 0.059 | 69.6% | <0.001 |
| Ethnicity | |||||||||||||||||
| Caucasians | 6,022/7,200 | 1.07(0.96–1.18) | 0.216 | 69.5% | <0.001 | 1.18(0.98–1.41) | 0.088 | 58.5% | 0.001 | 1.11(0.97–1.27) | 0.122 | 49.2% | 0.008 | 1.09(0.92–1.28) | 0.314 | 67.2% | <0.001 |
| Mixed | 2,176/2,852 | 1.07(0.78–1.47) | 0.687 | 83.9% | 0.002 | 1.17(0.55–2.48) | 0.676 | 83.9% | 0.002 | 1.14(0.90–1.45) | 0.279 | 56.4% | 0.076 | 1.08(0.58–2.00) | 0.816 | 81.0% | 0.005 |
| Asians | 3,078/4,471 | 1.27(0.87–1.87) | 0.216 | 91.7% | <0.001 | 1.60(0.67–3.80) | 0.287 | 90.6% | <0.001 | 1.42(0.71–2.85) | 0.326 | 89.6% | <0.001 | 1.23(1.01–1.49) | 0.044 | 70.0% | 0.001 |
| Cancer type | |||||||||||||||||
| Prostate cancer | 1,652/1,728 | 1.17(0.97–1.40) | 0.098 | 59.5% | 0.085 | 1.36(0.94–1.97) | 0.106 | 56.8% | 0.099 | 1.24(0.89–1.72) | 0.208 | 70.7% | 0.033 | 1.24(1.04–1.47) | 0.014 | 0.0% | 0.470 |
| Breast cancer | 3,595/3,665 | 1.02(0.79–1.31) | 0.878 | 82.4% | <0.001 | 1.11(0.70–1.75) | 0.669 | 71.3% | 0.001 | 1.07(0.84–1.38) | 0.576 | 46.1% | 0.072 | 1.12(0.87–1.43) | 0.385 | 78.3% | <0.001 |
| Colorectal cancer | 2,630/3,157 | 0.95(0.88–1.03) | 0.203 | 0.0% | 0.671 | 0.90(0.77–1.05) | 0.169 | 0.0% | 0.675 | 0.99(0.88–1.11) | 0.849 | 0.0% | 0.615 | 0.88(0.77–1.00) | 0.046 | 0.0% | 0.699 |
| Others | 3,399/5,973 | 1.17(0.98–1.40) | 0.081 | 82.7% | <0.001 | 1.34(0.92–1.94) | 0.127 | 81.1% | <0.001 | 1.25(0.95–1.65) | 0.104 | 78.2% | <0.001 | 1.18(0.98–1.42) | 0.083 | 63.0% | 0.002 |
| System of cancer | |||||||||||||||||
| Reproductive and breast cancer | 5,313/5,936 | 1.10(0.95–1.29) | 0.207 | 75.9% | <0.001 | 1.28(0.98–1.68) | 0.074 | 63.0% | 0.002 | 1.15(0.97–1.37) | 0.105 | 47.9% | 0.032 | 1.17(0.97–1.40) | 0.096 | 70.7% | <0.001 |
| Hematopoietic malignancy | 1,041/1,629 | 1.13(1.01–1.26) | 0.038 | 0.0% | 0.595 | 1.25(1.00–1.55) | 0.049 | 0.0% | 0.680 | 1.17(0.99–1.39) | 0.068 | 0.0% | 0.399 | 1.15(0.95–1.39) | 0.140 | 0.0% | 0.730 |
| Digestive system cancer | 4,398/6,428 | 0.99(0.86–1.13) | 0.838 | 73.4% | <0.001 | 0.94(0.70–1.25) | 0.658 | 70.4% | 0.001 | 1.01(0.81–1.27) | 0.928 | 71.7% | <0.001 | 0.95(0.82–1.09) | 0.454 | 47.5% | 0.055 |
| Others | 524/530 | 1.60(0.96–2.66) | 0.070 | 88.2% | <0.001 | 2.48(0.99–6.23) | 0.053 | 85.1% | 0.001 | 2.06(1.05–4.02) | 0.035 | 80.3% | 0.006 | 1.66(0.90–3.03) | 0.102 | 78.6% | 0.009 |
| Sample size | |||||||||||||||||
| <1000 | 3,685/4,312 | 1.13(0.94–1.37) | 0.200 | 81.6% | <0.001 | 1.32(0.92–1.90) | 0.129 | 74.8% | <0.001 | 1.29(1.03–1.62) | 0.027 | 64.3% | <0.001 | 1.15(0.92–1.43) | 0.224 | 73.3% | <0.001 |
| ≥1000 | 7,591/10,211 | 1.04(0.96–1.12) | 0.378 | 62.4% | 0.006 | 1.05(0.88–1.26) | 0.559 | 67.9% | 0.002 | 1.01(0.90–1.13) | 0.836 | 51.2% | 0.037 | 1.09(0.97–1.23) | 0.135 | 61.6% | 0.005 |
| Source of control | |||||||||||||||||
| Hospital-based | 7,498/9,828 | 1.13(0.98–1.30) | 0.087 | 83.6% | <0.001 | 1.26(0.94–1.68) | 0.118 | 81.3% | <0.001 | 1.21(0.98–1.49) | 0.073 | 77.7% | <0.001 | 1.13(0.98–1.31) | 0.100 | 71.1% | <0.001 |
| Population-based | 3,778/4,695 | 1.08(0.97–1.19) | 0.151 | 47.6% | 0.064 | 1.24(1.09–1.42) | 0.001 | 0.0% | 0.731 | 1.10(0.99–1.21) | 0.069 | 0.0% | 0.811 | 1.11(0.90–1.37) | 0.314 | 65.2% | 0.005 |